Market has misinterpreted the announcement not realising that it is much more significant than reporting the number of patients recruited. There is a strong indication that trials have been completed on multiple patients with desired results. The share price should start moving up in the coming weeks towards ATH, as the people analyse this piece of information and FOMO kicks in.
